USANA Health Sciences (NASDAQ:USNA)‘s stock had its “neutral” rating reaffirmed by research analysts at DA Davidson in a report released on Wednesday, Analyst Ratings Network reports. They currently have a $92.00 price target on the stock, up from their previous price target of $80.00. DA Davidson’s price target suggests a potential upside of 19.16% from the stock’s previous close.
The analysts wrote, “Q2 operating EPS of $1.72 was up ~55% from $1.11 last year, exceeding our $1.23 estimate and the 5-analyst Street mean of $1.33. Results were driven by sales increases in the Asia Pacific and North America/Europe segments, as well as a $1.2 million benefit from favorable exchange rates. The tax rate of 33.4% was 40bp higher than our forecast. Net sales of $189.1 million increased 17.5% year-over-year. On a segment basis, sales in North America grew 6.9%, SE Asia/Pacific was up 9.3%, China increased 36.3%, and North Asia climbed 1.5%. Total Active Associates’ growth was 8.1%, led by Greater China, which grew 18.4%. North Asia was the second fastest growing segment, up 12.5%. Active Associates in SE Asia/Pacific grew 3.4%, while North America was flat.”
Shares of USANA Health Sciences (NASDAQ: USNA) traded up 4.35% during mid-day trading on Wednesday, hitting $77.21. USANA Health Sciences has a 52 week low of $30.51 and a 52 week high of $87.40. The stock’s 50-day moving average is currently $74.23. The company has a market cap of $1.041 billion and a P/E ratio of 15.31.
USANA Health Sciences (NASDAQ:USNA) last posted its quarterly earnings results on Tuesday, July 23rd. The company reported $1.72 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.33 by $0.39. The company had revenue of $189.10 million for the quarter, compared to the consensus estimate of $176.60 million. During the same quarter last year, the company posted $1.11 earnings per share. USANA Health Sciences’s revenue was up 17.5% compared to the same quarter last year. USANA Health Sciences has set its FY13 guidance at $5.30-5.35 EPS. Analysts expect that USANA Health Sciences will post $5.47 EPS for the current fiscal year.
A number of other analysts have also recently weighed in on USNA. Analysts at Zacks downgraded shares of USANA Health Sciences from an “outperform” rating to a “neutral” rating in a research note to investors on Tuesday, June 25th. They now have a $78.40 price target on the stock. Analysts at Sidoti downgraded shares of USANA Health Sciences from a “buy” rating to a “neutral” rating in a research note to investors on Monday, June 17th.
Four equities research analysts have rated the stock with a hold rating, The stock has a consensus rating of “Hold” and an average price target of $69.68.
USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.